Genetically-modified hematopoietic stem cells and their progeny for widespread and efficient protein delivery to diseased sites: The case of lysosomal storage disorders

Current Gene Therapy

Volumn 12, Issue 5, 2012, Pages 381-388

  Biffi, Alessandra ^a  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Central nervous system; Gene therapy; Hematopoietic stem cells

Indexed keywords

ADENOVIRUS VECTOR; LENTIVIRUS VECTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD BRAIN BARRIER; CELL BASED GENE THERAPY; CELL ENGINEERING; ENZYME REPLACEMENT; GENE DELIVERY SYSTEM; GENE TRANSFER; GENETIC ENGINEERING; HEMATOPOIETIC STEM CELL; HUMAN; LYSOSOME; LYSOSOME STORAGE DISEASE; NONHUMAN; PROGENY; PROTEIN TARGETING; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; ENZYMES; GENETIC THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LYSOSOMAL STORAGE DISEASES;

EID: 84867000502     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312802762572     Document Type: Review

References (108)

1. Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiology of Disease 2010; 37(1): 13-25.
2. Neufeld EF. Lysosomal disease. Annu Rev Biochem 1991; 60: 257-80.
3. Suzuki K. Twenty five years of the psychosine hypothesis: a personal perspective of its history and present status. Neurochem Res 1998; 23(3): 251-9.
4. Ohmi K, Greenberg DS, Rajavel KS, et al. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 2003; 100: 1902-7.
5. Barranger JA, O'Rourke E. Lessons learned from the development of enzyme therapy for Gaucher disease. J Inherit Metab Dis 2001; 24(Suppl 2): 89-96.
6. Desnick RJ, Ioannou YA, Eng CM. In: Scriver CR BA, Sly WS, Valle D, (Eds). Metabolic and Molecular Bases of Inherited Diseases: McGraw-Hill; 2001. Pp. 3733-74.
7. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16.
8. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001; 344: 182-8.
9. Beck M. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet 2007; 121(1): 1-22.
10. Vogler C, Levy B, Grubb JH, et al. Overcoming the blood-brain barrier with high dose enzyme replacemnet therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci U S A 2005: 14777-7782.
11. Polito VA, Cosma MP. IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice. Am J Hum Genet 2009; 85(2): 296-301.
12. Matzner U, Lüllmann-Rauch R, Stroobants S, et al. Enzyme Replacement Improves Ataxic Gait and Central Nervous System Histopathology in a Mouse Model of Metachromatic Leukodystrophy. Mol Ther 2009; 17: 600-6 [Epub ahead of print]
13. Boado RJ, Zhang Y, Zhang Y, et al. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng 2007; 96(2): 381-91.
14. Rozaklis T, Beard H, Hassiotis S, et al. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA. Exp Neurol 2011; 230(1): 123-30.
15. Lachmann RH. Enzyme replacement therapy for lysosomal storage diseases. Curr Opin Pediatr 2011; 23(6): 588-93.
16. Brady RO, Murray GJ, Oliver KL, et al. Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. Pediatrics 1997; 100(6): E11.
17. Brooks DA, Kakavanos R, Hopwood JJ. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med 2003; 9(10): 450-3.
18. Reddy PS, Sakhuja K, Ganesh S, et al. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol Ther 2002; 5(1): 63-73.
19. Daly TM. AAV-mediated gene transfer to the liver. Methods Mol Biol 2004; 246: 195-9.
20. Hartung SD, Frandsen JL, Pan D, et al. Correction of metabolic, craniofacial, and neurologic abnormalities in MPSI mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther 2004; 9(6): 866-75.
21. Sferra TJ, Backstrom K, Chuansong W, et al. Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse. Mol Ther 2004; 10(3): 478-91.
22. McCormack JE, Edwards W, Sensintaffer J, et al. Factors affecting long-term expression of a secreted transgene product after intravenous administration of a retroviral vector. Mol Ther 2001; 3(4): 516-25.
23. Parker Ponder K, Melniczek JR, Xu L, et al. Therapeutical neonatal hepatic gene therapy in mucopolisaccharidosis VII dogs. Proc Natl Acad Sci U S A 2002; 99(20): 13102-07.
24. Mango RL, Xu L, Sands MS, et al. Neonatal retroviral vectormediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs. Mol Genet Metab 2004 82(1): 4-19.
25. McIntyre C, Byers S, Anson DS. Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated gene transfer. J Gene Med 2010; 12(9): 717-28.
26. Di Domenico C, Villani GR, Di Napoli D, et al. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector. Hum Gene Ther 2005; 16(1): 81-90.
27. Traas AM, Wang P, Ma X, et al. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy. Mol Ther 2007; 15(8): 1423-31.
28. Ruzo A, Garcia M, Ribera A, et al. Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice. Mol Ther 2012; 20(2): 254-66.
29. Fu H, Dirosario J, Killedar S, et al. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther 2011; 19(6): 1025-33.
30. Proescholdt MG, Hutto B, Brady LS, et al. Studies of cerebrospinal fluid flow and penetration into brain following lateral ventricle and cisterna magna injections of the tracer[14C]inulin in rat. Neuroscience 2000; 95(2): 577-92.
31. Rennels ML, Blaumanis OR, Grady PA. Rapid solute transport throughout the brain via paravascular fluid pathways. Adv Neurol 1990; 52: 431-9.
32. Rennels ML, Gregory TF, Blaumanis OR, et al. Evidence for a 'paravascular' fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res 1985; 326(1): 47-63.
33. Ghersi-Egea JF, Finnegan W, Chen JL, et al. Rapid distribution of intraventricularly administered sucrose into cerebrospinal fluid cisterns via subarachnoid velae in rat. Neuroscience 1996; 75(4): 1271-88.
34. Stroobants S, Gerlach D, Matthes F, et al. Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy. Hum Mol Genet 2011; 20(14): 2760-9.
35. Xu S, Wang L, El-Banna M, et al. Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther 2011; 19(10): 1842-8.
36. Dickson PI, Chen AH. Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: translating success in animal models to patients. Curr Pharm Biotechnol 2011; 12(6): 946-55.
37. Vuillemenot BR, Katz ML, Coates JR, et al. Intrathecal tripeptidylpeptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis. Mol Genet Metab 2011; 104(3): 325-37.
38. Ziegler RJ, Salegio EA, Dodge JC, et al. Distribution of acid sphingomyelinase in rodent and non-human primate brain after intracerebroventricular infusion. Exp Neurol 2011; 231(2): 261-71.
39. Passini MA, Lee EB, Heuer GG, et al. Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J Neurosci 2002; 22(15): 6437-46.
40. Cearley CN, Wolfe JH. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci 2007; 27(37): 9928-40.
41. Lin DS, Hsiao CD, Liau I, et al. CNS-targeted AAV5 gene transfer results in global dispersal of vector and prevention of morphological and function deterioration in CNS of globoid cell leukodystrophy mouse model. Mol Genet Metab 2011; 103(4): 367-77.
42. Cachon-Gonzalez MB, Wang SZ, Lynch A, et al. Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc Natl Acad Sci USA 2006; 103(27): 10373-8.
43. Ciron C, Desmaris N, Colle MA, et al. Gene therapy of the brain in the dog model of Hurler's syndrome. Ann Neurol 2006; 60(2): 204-13.
44. Desmaris N, Verot L, Puech JP, et al. Prevention of neuropathology in the mouse model of Hurler syndrome. Ann Neurol 2004; 56: 68-76.
45. Sevin C, Benraiss A, Van Dam D, et al. Intracerebral adenoassociated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy. Hum Mol Genet 2006; 15(1): 53-64.
46. McCown TJ. Adeno-Associated Virus (AAV) Vectors in the CNS. Curr Gene Ther 2011; 11(3): 181-8.
47. Lattanzi A, Neri M, Maderna C, et al. Widespread enzymatic correction of CNS tissues by a single intracerebral injection of therapeutic lentiviral vector in leukodystrophy mouse models. Hum Mol Genet 2010; 19(11): 2208-27.
48. Consiglio A, Quattrini A, Martino S, et al. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairment in affected mice. Nat Med 2001; 7(3): 310-6.
49. Barron KD. The microglial cell. A historical review. J Neurol Sci 1995; 134 Suppl: 57-68.
50. Brooks AI, Stein CS, Hughes SM, et al. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virusbased vectors. Proc Natl Acad Sci USA 2002; 99: 6216-21.
51. Luca T, Givogri MI, Perani L, et al. Axons mediate the distribution of arylsulfatase a within the mouse hippocampus upon gene delivery. Mol Ther 2005; 12(4): 669-79.
52. Vite CH, McGowan JC, Niogi SN, et al. Effective gene therapy for an inherited CNS disease in a large animal model. Ann Neurol 2005; 57(3): 355-64.
53. Hackett PB, Ekker SC, Largaespada DA, et al. Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv Genet 2005; 54: 189-232.
54. Ciron C, Desmaris N, Colle MA, et al. Gene therapy of the brain in the dog model of Hurler's syndrome. Ann Neurol 2006; 60(2): 204-13.
55. Sondhi D, Hackett NR, Peterson DA, et al. Enhanced Survival of the LINCL Mouse Following CLN2 Gene Transfer Using the rh.10 Rhesus Macaque-derived Adeno-associated Virus Vector. Mol Ther 2007; 15(3): 481-91.
56. Colle MA, Piguet F, Bertrand L, et al. Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Hum Mol Genet; 19(1): 147-58.
57. Worgall S, Sondhi D, Hackett NR, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008; 19(5): 463-74.
58. Givogri MI, Galbiati F, Fasano S, et al. Oligodendroglial progenitor cell therapy limits central neurological deficits in mice with metachromatic leukodystrophy. J Neurosci 2006; 26(12): 3109-19.
59. Neri M, Ricca A, di Girolamo I, et al. Neural stem cell gene therapy ameliorates pathology and function in a mouse model of globoid cell leukodystrophy. Stem Cells 2011; 29(10): 1559-71.
60. Biffi A, De Palma M, Quattrini A, et al. Correction of Metachromatic Leukodystrophy in the Mouse Model by Transplantation of Genetically Modified Hematopoietic Stem Cells. J Clin Invest 2004; 113(8): 1118-29.
61. Buchet D, Serguera C, Zennou V, et al. Long-term expression of beta-glucuronidase by genetically modified human neural progenitor cells grafted into the mouse central nervous system. Mol Cell Neurosci 2002; 19(2): 389-401.
62. Meng XL, Shen JS, Ohashi T, et al. Brain transplantation of genetically engineered human neural stem cells globally corrects brain lesions in the mucopolysaccharidosis type VII mouse. J Neurosci Res 2003; 74(2): 266-77.
63. Lacorazza HD, Flax JD, Snyder EY, et al. Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells. Nat Med 1996; 2(4): 424-9.
64. Krall WJ, Challita PM, Perlmutter LS, et al. Cells expressing human glucocerebrosidase from a retroviral vector repopulate macrophages and central nervous system microglia after murine bone marrow transplantation. Blood 1994; 83(9): 2737-48.
65. Sakurai K, Iizuka S, Shen JS, et al. Brain transplantation of genetically modified bone marrow stromal cells corrects CNS pathology and cognitive function in MPS VII mice. Gene Ther 2004; 11(19): 1475-81.
66. Shihabuddin LS, Numan S, Huff MR, et al. Intracerebral transplantation of adult mouse neural progenitor cells into the Niemann-Pick-A mouse leads to a marked decrease in lysosomal storage pathology. J Neurosci 2004; 24(47): 10642-51.
67. Eglitis MA, Mezey E. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci U S A 1997; 94: 4080-5.
68. Krivit W, Sung JH, Shapiro EG, et al. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant 1995; 4(4): 385-92.
69. Hoogerbrugge PM, Poorthuis BJ, Romme AE, et al. Effect of bone marrow transplantation on enzyme levels and clinical course in the neurologically affected twitcher mouse. J Clin Invest 1988; 81(6): 1790-4.
70. Ajami B, Bennet JL, Krieger C, et al. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci 2007; 10(12): 1538-43.
71. Mildner A, Schmidt H, Nitsche M, et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci 2007; 10(12): 1544-53.
72. Priller J, Flugel A, Wehner T, et al. Targeting gene-modified hematopoietic cells to central nervous system; use of green fluorescent proteine uncovers microglial engraftment. Nat Med 2001; 7(12): 1356-61.
73. Yeager AM, Shinn C, Shinohara M, et al. Hematopoietic cell transplantation in the twitcher mouse. The effects of pretransplant conditioning with graded doses of busulfan. Transplantation 1993; 56(1): 185-90.
74. Yeager AM, Shinohara M, Shinn C. Hematopoietic cell transplantation after administration of high-dose busulfan in murine globoid cell leukodystrophy (the twitcher mouse). Pediatr Res 1991; 29(3): 302-5.
75. Sano R, Tessitore A, Ingrassia A, et al. Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology. Blood 2005; 106(7): 2259-68.
76. Flugel A, Berkowicz T, Ritter T, et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 2001 May; 14(5): 547-60.
77. Priller J, Prinz M, Heikenwalder M, et al. Early and rapid engraftment of bone marrow-derived microglia in scrapie. J Neurosci 2006; 26(45): 11753-62.
78. Moritz T, Dutt P, Xiao X, et al. Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. Blood 1996; 88(3): 855-62.
79. Kokovay E, Cunningham LA. Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease. Neurobiol Dis 2005; 19(3): 471-8.
80. Malm TM, Koistinaho M, Parepalo M, et al. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis 2005; 18(1): 134-42.
81. Simard AR, Soulet D, Gowing G, et al. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006; 49(4): 489-502.
82. Stalder AK, Ermini F, Bondolfi L, et al. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J Neurosci 2005; 25(48): 11125-32.
83. McMahon EJ, Suzuki K, Matsushima GK. Peripheral macrophage recruitment in cuprizone-induced CNS demyelination despite an intact blood-brain barrier. J Neuroimmunol 2002; 130(1-2): 32-45.
84. Biffi A, Capotondo A, Fasano S, et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest 2006; 116(1): 3070-82.
85. Wu YP, Proia RL. Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice. Proc Natl Acad Sci U S A 2004; 101(22): 8425-30.
86. Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant 2003; 31: 229-39.
87. Krivit W, Aubourg P, Shapiro E, et al. Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Curr Opin Hematol 1999; 6(6): 377-82.
88. Staba SL, Escolar ML, Poe M, et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004; 350(19): 1960-9.
89. Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of Umbilical-Cord Blood in Babies with Infantile Krabbe's Disease. N Engl J Med 2005; 352(20): 2069-81.
90. Asheuer M, Pflumio F, Benhamida S, et al. Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein. Proc Natl Acad Sci U S A 2004; 101(10): 3557-62.
91. Krivit W. Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv Pediatr 2002; 49: 359-78.
92. Prasad VK, Kurtzberg J. Emerging trends in transplantation of inherited metabolic diseases. Bone Marrow Transplant 2008; 41(2): 99-108.
93. Martin JJ, Ceuterick C, Mercelis R, et al. Pathology of peripheral nerves in metachromatic leucodystrophy. A comparative study of ten cases. J Neurol Sci 1982; 53(1): 95-112.
94. Bredius RG, Laan LA, Lankester AC, et al. Early marrow transplantation in a pre-symptomatic neonate with late infantile metachromatic leukodystrophy does not halt disease progression. Bone Marrow Transplant 2007; 39(5): 309-10.
95. Proia RL, Wu YP. Blood to brain to the rescue. J Clin Invest 2004; 113(8): 1108-10.
96. Orchard PJ, Wagner JE. Leukodystrophy and gene therapy with a dimmer switch. N Engl J Med 2011; 364(6): 572-3.
97. Matzner U, Harzer K, Learish RD, et al. Long-term expression and transfer of arylsulfatase A into brain of arylsulfatase A-deficient mice transplanted with bone marrow expressing the arylsulfatase A cDNA from a retroviral vector. Gene Ther 2000; 7(14): 1250-7.
98. Matzner U, Schestag F, Hartmann D, et al. Bone marrow stem cell gene therapy of arylsulfatase A-deficient mice, using an arylsulfatase A mutant that is hypersecreted from retrovirally transduced donor-type cells. Hum Gene Ther 2001; 12(9): 1021-33.
99. Gentner B, Visigalli I, Hiramatsu H, et al. Identification of Hematopoietic Stem Cell-specific miRNAs Enables Gene Therapy of Globoid Leukodystrophy. Science Transl Med 2010; 2(58): 58ra84.
100. Visigalli I, Ungari S, Martino S, et al. The galactocerebrosidase enzyme contributes to the maintenance of a functional hematopoietic stem cell niche. Blood 2010; 116(11): 1857-66.
101. Visigalli I, Delai S, Politi LS, et al. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects Mucopolysaccharidosis type I phenotype in the mouse model. Blood 2010; 116(24): 5130-9.
102. Langford-Smith A, Wilkinson FL, Langford-Smith KJ, et al. Hematopoietic Stem Cell and Gene Therapy Corrects Primary Neuropathology and Behavior in Mucopolysaccharidosis IIIA Mice. Mol Ther 2012; 20(8): 1610-21.
103. Capotondo A, Cesani M, Pepe S, et al. Safety of Arylsulfatase A Overexpression for Gene Therapy of Metachromatic Leukodystrophy. Hum Gene Ther 2007; 18: 821-36.
104. Biffi A, Cesani M. Human hematopoietic stem cells in gene therapy: pre-clinical and clinical issues. Curr Gene Ther 2008; 8(2): 135-46.
105. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24(6): 687-96.
106. Montini E, Cesana D, Schmidt M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009; 119(4): 964-75.
107. Biffi A, Bartolomae CC, Cesana D, et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 2011; 117(20): 5332-9.
108. Scaramuzza S, Biasco L, Ripamonti A, et al. Preclinical Safety and Efficacy of Human CD34(+) Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich Syndrome 2012; Feb. 28.